Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
15 studies found for:    Gd-DOTA
Show Display Options
Rank Status Study
1 Recruiting Validation of New Markers of Glomerular Filtration Rate: Dota Gadolinium and Calcium EDTA (MultiGFR)
Conditions: Renal Insufficiency, Chronic;   Kidney Diseases
Interventions: Drug: Calcium EDTA;   Drug: Gd-DOTA
2 Completed
Has Results
Safety and Efficacy Evaluation of DOTAREM® in MRI of Central Nervous System (CNS) Lesions
Conditions: Diagnostic Self Evaluation;   Central Nervous System Diseases
Interventions: Drug: Dotarem (gadoterate meglumine);   Drug: Magnevist (gadopentetate dimeglumine)
3 Completed
Has Results
Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease
Condition: Peripheral Arterial Disease
Interventions: Drug: Dotarem;   Drug: Gadovist
4 Recruiting DCE-MRI Using Dotarem® in Evaluation of Therapeutic Response to Sorafenib in Patients With Advanced Stage HCC
Condition: Hepatocellular Carcinoma
Intervention: Drug: Meglumine Gadoterate
5 Recruiting Crossover Comparison of MultiHance and Dotarem
Condition: Brain Disease
Interventions: Drug: Gadobenate;   Drug: Gadoterate
6 Terminated
Has Results
Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
Condition: Renal Artery Stenosis
Interventions: Drug: Gadoterate meglumine (Dotarem);   Other: Time of Flight Magnetic Resonance Angiography
7 Completed Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
Conditions: Carotid Arterial Disease;   Vertebral Arterial Disease
Interventions: Drug: Dotarem;   Other: TOF MRA
8 Completed Carotid and Vertebral Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time Of Flight (TOF)
Condition: Carotid or Vertebral Arterial Disease
Interventions: Drug: Dotarem;   Other: TOF MRA
9 Completed Contrast Enhanced MRI of the CNS - Patients With Known Cerebral Neoplastic Lesions.
Condition: Neoplastic CNS Lesions
Interventions: Drug: Gadovist®  (Gadobutrol, BAY86-4875);   Drug: Dotarem
10 Terminated Renal Magnetic Resonance Angiography (MRA) Study Comparing Dotarem and Time-Of-Flight (TOF)
Condition: Renal Arterial Disease
Intervention: Drug: Dotarem
11 Completed Renal Safety Evaluation After Dotarem-enhanced MRI
Condition: Nephropathy
Interventions: Drug: Dotarem;   Procedure: non-enhanced MRI
12 Not yet recruiting Kidney Response to Sepsis Affects Angiogenic Balance and Likelihood of CCI and PICS
Condition: Sepsis
Interventions: Drug: Iohexol;   Drug: Dotarem
13 Completed Safety and Dialysability of Dotarem® in Dialysed Patients
Condition: End-stage Renal Failure
Intervention: Drug: Dotarem
14 Completed
Has Results
DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Diseases
Condition: Peripheral Arterial Disease
Intervention: Other: Contrast-enhanced MRA - Imaging examination
15 Recruiting Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors
Condition: Primary Brain Tumor
Interventions: Drug: Dotarem®;   Drug: Gadovist®/Gadavist®

Indicates status has not been verified in more than two years